---
title: "Insilico Medicine and Hygtia Therapeutics collaborate on ISM8969 for CNS diseases, sharing 50% rights globally."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273150222.md"
description: "Insilico Medicine and Hygtia Therapeutics, a start-up supported by the Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have recently formed an exclusive partnership to further develop ISM8969 on a global scale. This collaboration involves a shared 50% ownership of worldwide rights between the two companies."
datetime: "2026-01-21T00:17:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273150222.md)
  - [en](https://longbridge.com/en/news/273150222.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273150222.md)
---

# Insilico Medicine and Hygtia Therapeutics collaborate on ISM8969 for CNS diseases, sharing 50% rights globally.

Insilico Medicine and Hygtia Therapeutics, a start-up supported by the Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have recently formed an exclusive partnership to further develop ISM8969 on a global scale. This collaboration involves a shared 50% ownership of worldwide rights between the two companies.

### Related Stocks

- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [HOTH.US](https://longbridge.com/en/quote/HOTH.US.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [01650.HK](https://longbridge.com/en/quote/01650.HK.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [516610.CN](https://longbridge.com/en/quote/516610.CN.md)
- [XHS.US](https://longbridge.com/en/quote/XHS.US.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [600196.CN](https://longbridge.com/en/quote/600196.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [159898.CN](https://longbridge.com/en/quote/159898.CN.md)
- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159883.CN](https://longbridge.com/en/quote/159883.CN.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)

## Related News & Research

- [EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies](https://longbridge.com/en/news/286908929.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)